<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part4">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>4</PartID>
        <PartNumber>Part III</PartNumber>
        <PartSequenceNumber>4</PartSequenceNumber>
        <PartTitle>Angiogenesis</PartTitle>
        <PartChapterCount>5</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap18" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>18</ChapterID>
          <ChapterNumber>Chapter 18</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_18</ChapterDOI>
          <ChapterSequenceNumber>18</ChapterSequenceNumber>
          <ChapterTitle Language="En">Bevacizumab in Advanced Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>207</ChapterFirstPage>
          <ChapterLastPage>214</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>4</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Aymen</GivenName>
                <GivenName>A.</GivenName>
                <FamilyName>Elfiky</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff1_18" CorrespondingAffiliationID="Aff1_18">
              <AuthorName DisplayOrder="Western">
                <GivenName>William</GivenName>
                <GivenName>Kevin</GivenName>
                <FamilyName>Kelly</FamilyName>
              </AuthorName>
              <Contact>
                <Email>wm.kevin.kelly@jefferson.edu</Email>
                <Email>wm.kevin.kelly@yale.edu</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_18">
              <OrgDivision>Solid Tumor Oncology, Department of Medical Oncology, Associate Director of Translation Research, Jefferson Kimmel Cancer Center</OrgDivision>
              <OrgName>Thomas Jefferson University</OrgName>
              <OrgAddress>
                <Street>Suite 314</Street>
                <City>Philadelphia</City>
                <State>PA</State>
                <Postcode>19107</Postcode>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_18" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Prostate cancer is the leading non-cutaneous malignancy in American men. Only the combination of docetaxel and prednisone has been shown to improve survival in patients with metastatic castration-resistant prostate cancer. Typically responses to docetaxel in patients with castrate-resistant disease are modest and additional therapies are needed. Angiogenesis has been shown to be a prerequisite event for tumor growth and metastasis in prostate cancer. Several strategies have been used to target angiogenesis in prostate cancer, which include blocking of pro-angiogenic factors via monoclonal antibodies or small-molecule inhibitors that target downstream signaling pathways for angiogenesis, direct inhibition of endothelial cells, or targeting other receptors involved in cell adhesion, proliferation, and survival. The following sections will discuss further the rationale for targeting the angiogenesis pathway in prostate cancer and the emergence of bevacizumab as a promising agent for the treatment of prostate cancer.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Angiogenesis</Keyword>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Drugs</Keyword>
            <Keyword>Bevacizumab</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1">
            <Heading>Mechanism of Angiogenesis</Heading>
            <Para TextBreak="No">For survival, tumor cells must obtain a steady supply of oxygen and nutrients needed to support metabolic activity. A tumor that relies on existing vasculature can reach a size of only about 2 mm. In tumor cells, increased production of pro-angiogenic factors occurs as the result of a phenomenon known as the “angiogenic switch.” Pathological angiogenesis results from disruption of the regulatory processes that normally maintain the stability of the vascular system. Although usually confined to a localized area, the growth of new blood vessels during pathological angiogenesis is excessive and it often involves the intrusion of these vessels into an area where their presence is harmful. Growth factors generated as a result of the “angiogenic switch” enable a tumor to increase its supply of nutrients via tumor angiogenesis. Tumor angiogenesis begins when vascular endothelial growth factor (VEGF) and other growth factors diffuse away from the tumor and come into contact with established blood vessels of surrounding tissues. These factors activate endothelial cells that line the walls of existing vessels, trigger the angiogenic cascade, and lead to the sprouting of new capillaries [<CitationRef CitationID="CR1_18">1</CitationRef>].</Para>
            <Para TextBreak="No">VEGF plays a central role in the regulation of angiogenesis. Many environmental factors stimulate VEGF expression, including hypoxia, low pH, hormones (e.g., progesterone, estrogen), growth factors (e.g., epidermal growth factor [EGF], TGF-β[beta], bFGF, PDGF, insulin-like growth factor [IGF]-1), and cytokines (e.g., IL-1α[alpha], IL-6). Tumorigenic mutations involving p53, p73, src, ras, vHL, and Bcr-Abl can also stimulate VEGF expression. VEGF binds and activates its receptor (VEGFR), resulting in stimulation of downstream signaling cascades such as phospholipase C, protein kinase C, the cytoplasmic tyrosine kinase src, αvβ5 integrins, phosphatidylinositol-3-kinase, ras, and MAP kinase. These downstream signaling pathways in endothelial cells lead to inhibition of apoptosis, stimulation of mitosis, and cytoskeletal changes associated with motility [<CitationRef CitationID="CR1_18">1</CitationRef>].</Para>
            <Para TextBreak="No">VEGF (also known as VEGF-A) is part of a family of related proteins with similar structural motifs, including placenta growth factor (PlGF), VEGF-B, VEGF-C, VEGF-D, and VEGF-E (viral VEGF homolog), identified in the parapoxvirus Orf virus (Fig. <InternalRef RefID="Fig1">18.1</InternalRef>). The family of VEGF proteins binds to several different VEGFRs with distinct binding and signaling properties. VEGFR1 (Flt-1), VEGFR2 (Flk-1, KDR), and VEGFR3 (Flt-4) have similar structural features and form homodimers upon ligand binding. Alternative splicing leads to the production of a soluble form of VEGFR-1, which does not bind to the membrane and functions as a negative regulator of VEGF signaling. The neuropilins, a distinct family of receptors, also interact with members of the VEGF family. Neuropilin-1 may function as co-receptor, enhancing VEGF interactions with VEGFR2. VEGFR1 interacts with PlGF, VEGF-B, and VEGF-A. The function of VEGFR1 remains to be elucidated. VEGFR1 signaling is only weakly activated by VEGF. VEGFR1 may function as a decoy receptor, much like soluble VEGFR1. VEGFR2 interacts with VEGF-C and D in addition to VEGF. This receptor is the major mediator of the mitogenic and angiogenic effects of VEGF. VEGFR-3 only interacts with VEGF-C and D and is involved in lymphangiogenesis [<CitationRef CitationID="CR1_18">1</CitationRef>].<Figure Category="Standard" Float="Yes" ID="Fig1">
                <Caption Language="En">
                  <CaptionNumber>Fig. 18.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>VEGF family pathways</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO1_18">
                  <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-829-4_18_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
            <Para TextBreak="No">Because tumors require new blood vessel development in order to grow and metastasize, tumor vasculature provides a useful target for anticancer therapy. In preclinical models, therapies that inhibit the activity of the VEGF pathway have been shown to slow tumor progression. Therapies that inhibit the VEGF pathway in combination with chemotherapy or radiation therapy has been shown to be synergistic in preclinical models. VEGF is over-expressed in many types of human tumors, and its over-expression is frequently associated with malignant progression. Inhibiting VEGF represents a promising anticancer approach, as it targets the key regulator of angiogenesis. A mouse monoclonal antibody that neutralizes the activity of human VEGF (A.4.6.1) is the precursor antibody to Bevacizumab [Avastin<Superscript>TM</Superscript> (BV)]. BV is a recombinant humanized monoclonal antibody that binds to VEGF with high specificity and affinity, resulting in potent VEGF-neutralizing activity. Once bound, BV prevents VEGF interactions with VEGFR-1 (Flt-1) and VEGFR-2 (KDR) on the surface of endothelial cells, inhibiting VEGF-stimulated downstream signaling events. The estimated half-life of Bevacizumab is about 20 days (with a range of 11–50 days) [<CitationRef CitationID="CR2_18">2</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Rationale for Targeting the Angiogenesis Pathway in Prostate Cancer</Heading>
            <Para TextBreak="No">Inhibition of angiogenesis prevents the growth of tumor cells at the primary site and can prevent the emergence of metastasis [<CitationRef CitationID="CR3_18">3</CitationRef>]. Efforts to inhibit angiogenesis as a means of controlling the growth and spread of cancer cells began more than 30 years ago when it was demonstrated that progressive tumor growth is contingent upon formation of new vessels that support proliferation [<CitationRef CitationID="CR4_18">4</CitationRef>–<CitationRef CitationID="CR6_18">6</CitationRef>]. With the implication of tumor angiogenesis in the pathological progression of a number of tumor models, numerous angiogenic growth factors, many of which may be targeted with modern drugs, have been identified. These include VEGF, platelet-derived endothelial cell growth factor (PD-ECGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), IGFs, angiogenin, thrombospondin, angiopoeitins, and integrins [<CitationRef CitationID="CR7_18">7</CitationRef>]. Additionally, early studies importantly demonstrated that higher microvessel density counts, a measure of angiogenesis, was associated with metastasis in solid tumors such as breast, lung, and bladder cancer [<CitationRef CitationID="CR8_18">8</CitationRef>–<CitationRef CitationID="CR11_18">11</CitationRef>], and was considered a negative prognostic indicator for several solid tumors, including prostate cancer [<CitationRef CitationID="CR12_18">12</CitationRef>]. Weidner et al. reported on 74 radical prostatectomy specimens that were stained for endothelial cells using factor VIII-related antigen and in which microvessel density was counted per 200 fields [<CitationRef CitationID="CR12_18">12</CitationRef>]. After a median follow-up of between 30 and 50 months, 29 of the 74 patients were found to have metastases. The mean number of microvessels counted for the patients with metastatic disease was 76.8 microvessels per 200 field (median, 66; SD, 44.6), a much higher count compared with the 39.2 microvessels per 200 field (median, 36; SD, 18.6) (<Emphasis Type="Italic">P</Emphasis>&lt; 0.0001) found in the 45 patients who did not develop metastasis during the length of the follow-up period. This suggests that microvessel density appears to be a predictor of tumor metastasis in prostate cancer. Furthermore, this increase in microvessel density was limited to invasive cancer areas and was notably different from surrounding benign areas of prostate tissue within the same patient [<CitationRef CitationID="CR13_18">13</CitationRef>]. Such observations have supported an increased focus on angiogenesis as a therapeutic target in prostate cancer.</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>VEGF Targeted Inhibition</Heading>
            <Para TextBreak="No">The use of angiogenesis inhibitors is rapidly emerging as a promising treatment strategy in a variety of solid tumors, currently including prostate cancer [<CitationRef CitationID="CR14_18">14</CitationRef>]. Importantly, the inevitable emergence of drug resistance that is seen with the use of cytotoxic chemotherapy alone may be overcome by targeting endothelial cells that possess little or no inherent mutation [<CitationRef CitationID="CR15_18">15</CitationRef>]. In addition, there is evidence suggesting enhanced efficacy of cytotoxic chemotherapy when it is combined with specific angiogenesis inhibitors as a result of vessel normalization and improvement in intratumoral or interstitial fluid pressure, allowing for better delivery of chemotherapy to areas of tumor [<CitationRef CitationID="CR16_18">16</CitationRef>, <CitationRef CitationID="CR17_18">17</CitationRef>].</Para>
            <Para TextBreak="No">Specific strategies, which have been used to target angiogenesis in prostate cancer, include blocking of pro-angiogenic factors such as VEGF via monoclonal antibodies such as bevacizumab or other small molecule inhibitors targeting downstream signaling pathways for angiogenesis, direct inhibition of endothelial cells, or targeting other receptors involved in cell adhesion, proliferation, and survival [<CitationRef CitationID="CR18_18">18</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>The Clinical Role of Bevacizumab in Prostate Cancer</Heading>
            <Section2 ID="Sec5">
              <Heading>Preclinical Data</Heading>
              <Para TextBreak="No">VEGF plays a role in the pathogenesis and progression of human prostate cancer [<CitationRef CitationID="CR19_18">19</CitationRef>, <CitationRef CitationID="CR20_18">20</CitationRef>]. Flk-1/KDR receptors are expressed in human prostate cancer, and their presence correlates with higher grade lesions [<CitationRef CitationID="CR21_18">21</CitationRef>]. VEGF is present in both localized and metastatic prostate tumors as well as the plasma of patients with metastatic disease, and increasing expression correlates with disease progression [<CitationRef CitationID="CR22_18">22</CitationRef>–<CitationRef CitationID="CR24_18">24</CitationRef>]. In patients with castrate-resistant disease, both plasma and urine VEGF levels are independent predictors of survival [<CitationRef CitationID="CR25_18">25</CitationRef>, <CitationRef CitationID="CR26_18">26</CitationRef>]. In vivo and in situ molecular analysis demonstrated that castration leads to tumor regression and concomitant decrease in VEGF expression [<CitationRef CitationID="CR27_18">27</CitationRef>, <CitationRef CitationID="CR28_18">28</CitationRef>]. Subsequently, replacement of androgens to long term castrated rats stimulated eightfold increase rise in VEGF content. In studies with the Shionogi murine tumor (an androgen-dependent mammary tumor), castration leads to tumor regression with a marked decrease in VEGF within 1 week. Once these tumors relapse in the absence of androgens, the dominant angiogenic factor is VEGF.</Para>
              <Para TextBreak="No">Antibodies to VEGF have caused tumor regression in preclinical prostate tumor models [<CitationRef CitationID="CR29_18">29</CitationRef>–<CitationRef CitationID="CR31_18">31</CitationRef>]. In human prostate cancer xenograft, an oral inhibitor of VEGF (ZD6474) produced greater inhibition of tumor growth than orchiectomy but increased tumor necrosis was observed when ZD6474 was combined with orchiectomy. In studies that evaluated, androgen-independent AT-1 prostate cancer cells that were grown inside the ventral prostate of adult non-castrated rats, ZD6474 decreased tumor vascular density, increased tumor hypoxia and apoptosis, and decreased tumor growth [<CitationRef CitationID="CR32_18">32</CitationRef>]. Similar effects were seen with castration that suggested castration and inhibition of VEGF may work through similar mechanisms. In these studies, the combination of ZD6474 and castration had synergistic effects on the tumor growth.</Para>
              <Para TextBreak="No">These studies suggests that VEGF pathway specifically plays a critical role in development and progression of prostate cancer, and that inhibitors of the VEGF signaling in combination with other standard treatments may improve the outcomes of patients with prostate cancer.</Para>
            </Section2>
            <Section2 ID="Sec6">
              <Heading>Success of Bevacizumab in Cancer</Heading>
              <Para TextBreak="No">Bevacizumab has been approved by the FDA for first- and second-line therapy of metastatic colorectal cancer (CRC), first-line therapy of non-small cell lung cancer (NSCLC), and more recently metastatic HER2-negative breast cancer. In patients with CRC, bevacizumab was shown to extend patients’ lives by about 5 months when given intravenously as a combination treatment along with the standard regimen of ironotecan, 5-fluorouracil (5FU), and leucovorin [<CitationRef CitationID="CR33_18">33</CitationRef>]. In the second-line setting, an absolute 17% improvement in overall survival (OS) and a 26% relative reduction in risk of death has been shown in patients receiving the combination of bevacizumab plus FOLFOX-4 compared with those receiving FOLFOX-4 alone [<CitationRef CitationID="CR34_18">34</CitationRef>]. This study is noteworthy as it was the first Phase III study to demonstrate the ability of bevacizumab to enhance the efficacy of an oxaliplatin-based regimen.</Para>
              <Para TextBreak="No">The recommendation for the initial systemic treatment of patients with unresectable, locally advanced, recurrent, or metastatic, nonsquamous, NSCLC is based on the demonstration of a statistically significant improvement in OS in patients receiving bevacizumab with carboplatin and paclitaxel compared with those receiving carboplatin and paclitaxel alone [<CitationRef CitationID="CR35_18">35</CitationRef>].</Para>
              <Para TextBreak="No">The recent approval in breast cancer was based on the demonstration of an improvement in progression-free survival (PFS) in patients receiving bevacizumab with paclitaxel compared with those receiving paclitaxel alone as a first-line treatment for metastatic breast cancer [<CitationRef CitationID="CR36_18">36</CitationRef>].</Para>
              <Para TextBreak="No">Most of the data elucidating the toxicities associated with bevacizumab have come from trials in CRC. Specific adverse effects, which have been attributed to bevacizumab, include hemorrhage (2–9.3%), thromboembolism (0–19%), proteinuria (1–28%), hypertension (7–25%), and perforation (0–3.3%).</Para>
            </Section2>
            <Section2 ID="Sec7">
              <Heading>Clinical Trials in Castration-Resistant Prostate Cancer</Heading>
              <Para TextBreak="No">Bevacizumab is a humanized monoclonal antibody that was developed from a murine antihuman VEGF monoclonal antibody that functions as an inhibitor of all major isoforms of VEGF-A [<CitationRef CitationID="CR37_18">37</CitationRef>]. A series of phase II and III clinical trials are being conducted to evaluate response to single-agent therapy as well as response to therapy in combination with other agents, which have demonstrated effect on prostate cancer and offered the potential of a synergistic effect when administered with bevacizumab (Table <InternalRef RefID="Tab1">18.1</InternalRef>). Bevacizumab as a single agent in castration-resistant prostate cancer has shown modest clinical activity. In a phase II study, 15 patients with castration-resistant disease were treated with 10 mg/kg rhuMAb VEGF every 14 days for six infusions followed by additional treatment for selected patients exhibiting a response or stable disease. After 12 weeks of therapy, none of the 15 patients evaluable for tumor response had an objective complete or partial response. Three possible mixed responses were observed. No patient achieved a &gt;50% decrease in serum PSA, although four patients (27%) had a PSA decline of &lt;50%. The median time to objective progression was 3.9 months, and the median time to PSA progression was 2 months. Toxicity was generally mild with asthenia present in 6/15 (40%). Two patients developed severe hyponatremia, although the association with rhuMAb VEGF was unclear. The conclusion was that single-agent rhuMAb VEGF in this dose and schedule did not produce significant objective responses in this population. It was recommended that further development of this agent in prostate cancer should include its evaluation in combination with other therapies [<CitationRef CitationID="CR38_18">38</CitationRef>].<Table Float="Yes" ID="Tab1">
                  <Caption Language="En">
                    <CaptionNumber>Table 18.1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Selected clinical trials of bevacizumab in prostate cancer</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="4">
                    <colspec colname="c1" colnum="1"/>
                    <colspec colname="c2" colnum="2"/>
                    <colspec colname="c3" colnum="3"/>
                    <colspec colname="c4" colnum="4"/>
                    <thead>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Clinical trials</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Study designation</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Disease designation</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Agents</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry colname="c1">
                          <SimplePara>CALGB 9006</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Phase II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>HRPC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Bevacizumab, docetaxel, and estramustine</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>NCI-04-C-0257</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Phase II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>HRPC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Bevacizumab, thalidomide, and docetaxel</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>CALGB 90401</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Phase III</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>HRPC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Docetaxel and prednisone with or without bevacizumab</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>WSU-2006-064</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Phase II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>HRPC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Bevacizumab</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>NCT00321646</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Phase II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>High-risk, localized PC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Neoadjuvant Bevacizumab plus Docetaxel before surgery</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>BRIVMRC-3031500</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Phase II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>High-risk, locally advanced PC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Bevacizumab plus ADT and RT</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>NCT00574769</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Phase I/II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>HRPC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Bevacizumab plus Docetaxel and RAD001 (mTOR inhibitor)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>TORI GU-01</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Phase II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>High-risk, localized PC</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Adjuvant Bevacizumab plus erlotinib following surgery</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>NCT00658697</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Phase II</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Rising PSA after local therapy</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Bevacizumab, Docetaxel, and ADT followed by continued Bevacizumab and ADT</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                </Table>
              </Para>
              <Para TextBreak="No">Because of the encouraging safety profile in prostate cancer and data from other malignancies showing enhanced clinical activity and benefit when combined with a cytotoxic agent, several combinational studies have been done. The investigators from the Cancer and Leukemia Group B (CALGB) performed a phase II trial investigating the role of bevacizumab with estramustine and docetaxel in patients with progressive castrate metastatic prostate cancer (CALGB 90006<Emphasis Type="Underline">)</Emphasis> [<CitationRef CitationID="CR39_18">39</CitationRef>]. Seventy-nine patients were treated with this combination (EMP-280 mg po TID days 1–5; Docetaxel 70 mg/m<Superscript>2</Superscript> – day 2; Bevacizumab 15 mg/kg over 30 min-day 2). Typical premedication for Docetaxel was given, and daily 2 mg of coumadin was administered to help prevent any thromboembolic disease related to the estramustine. Patients tolerated the therapy well. There was one death due to mesenteric vein thrombosis, one unrelated death due to a perforated sigmoid colon diverticulum, two patients with a CNS bleed, and two patients each with pulmonary embolism and deep venous thrombosis. Although these thromboembolic events were of concern, the overall incidence was not dramatically higher than what has been observed with estramustine and docetaxel without bevacizumab. An increase in neutropenia without neutropenic fever was observed. Additionally, an increased number of infections were also seen. The other toxicities were similar to what were published studies from Savarese and colleagues with estramustine, docetaxel, and hydrocortisone [<CitationRef CitationID="CR40_18">40</CitationRef>]. Perhaps, most importantly, the results observed with this combination compared favorably with other concurrent combinations tested by the CALGB. Compared with another CALGB triplet trial in which carboplatin was added to estramustine and docetaxel (CALGB 99813) [<CitationRef CitationID="CR41_18">41</CitationRef>], the use of bevacizumab resulted in a post-therapy PSA decline in 58 out of 72 (81%) patients compared with 68% of the patients treated with the carboplatin regimen, median time to objective disease progression of 9.7 months compared with 8.1, median time to PSA failure of 9.9 vs. 9 months, and OS of 21 months compared with 18 months. DiLorenzo et al. also evaluated the combination of docetaxel (60 mg/m<Superscript>2</Superscript>) and bevacizumab (10 mg/kg) every 3 weeks in patients with castrate-resistant disease, who had been treated with up to two prior chemotherapy regimens with one being docetaxel. Twenty heavily pretreated patients were enrolled, 11 (55%) of the patients had major PSA declines posttherapy and one third of the evaluable patients achieved a partial response [<CitationRef CitationID="CR42_18">42</CitationRef>]. Of interest, four patients who had no response to docetaxel previously had significant post-therapy PSA decline with the combination. This would suggest that bevacizumab may reverse docetaxel resistance in some patients either by improving drug delivery or by another mechanism that still needs to be elucidated.</Para>
              <Para TextBreak="No">Colleagues at the National Cancer Institute (NCI) conducted a trial using the combination of bevacizumab (15 mg/kg) with docetaxel (75 mg/m<Superscript>2</Superscript>) every 3 weeks, prednisone 5 mg twice daily, and thalidomide 200 mg every night, with thromboprophylaxis. Sixty evaluable patients with unfavorable characteristics evidenced by a high Gleason score and a short PSA doubling time were enrolled. Ninety percent of patients receiving the combination therapy had PSA declines of ≥ 50%, and 88% achieved a PSA decline of ≥ 30% within the first 3 months of treatment. The median time to progression was 18.3 months, and the median overall survival was 28.2 months [<CitationRef CitationID="CR43_18">43</CitationRef>]. Significant toxicities reported were febrile neutropenia, syncope, GI perforation or fistula, thrombosis, and grade 3 bleeding.</Para>
              <Para TextBreak="No">These encouraging data have lead to a randomized phase III double-blinded study comparing Docetaxel and prednisone with bevacizumab or placebo (CALGB 90401) [<CitationRef CitationID="CR44_18">44</CitationRef>] (Fig. <InternalRef RefID="Fig2">18.2</InternalRef>). Preliminary results of the study have been reported. In an intent to treat analysis there was no significant difference in the median survival between the two arms (22.6 for the Docetaxel, prednisone and bevacizumab vs. 21.6 months for Docetaxel and prednisone alone, p = 0.181; Hazard ratio (HR) = 0.91). The median progression free survival favored patients treated on the bevacizumab arm (9.9 months verses 7.5 months, p&lt; 0.0001; HR = 0.77). Secondary endpoints of ≥ 50% post-therapy PSA declines (69.5% vs. 53.2%, p =.0002) and objective response proportions (57.9 % vs. 53.2%, p =.0113) significantly favored the bevacizumab treated patients. Overall summary for maximum hematologic and non-hematologic adverse events showed that there was an increase in morbidity and mortality associated with docetaxel, prednisone and bevacizumab in this elderly population. This study showed that the addition of bevacizumab to docetaxel and prednisone did increase progression free survival; objective and PSA response along with the toxicity, but not the overall survival. The lack of survival benefit may have been related to the heterogeneity of the study population as well as impact of secondary chemotherapies on the primary outcome of the study. Further randomized studies are needed to define the role of anti-angiogenic therapy in this metastatic castrate resistant prostate cancer. (Kelly, WK et al. Jouranl of Clinical Oncology Proceeding 2010 ASCO, LBA 4511, Chicago, Ill June 4-8, 2010).<Figure Category="Standard" Float="Yes" ID="Fig2">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 18.2</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>CALGB 90401 clinical trial treatment schema</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject ID="MO2_18">
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-829-4_18_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
            </Section2>
            <Section2 ID="Sec8">
              <Heading>Bevacizumab in Castrate-Sensitive Prostate Cancer</Heading>
              <Para TextBreak="No">Preclinical data demonstrate a strong association between castration and VEGF expression as well as a synergy between androgen deprivation and blockage of the VEGF pathway. This would suggest that castration and VEGF inhibition may lead to increased prostate cell death and prolong the effects of castration. Moreover, it is foreseeable that bringing bevacizumab to the forefront in treating patients with castrate-sensitive disease could potentially improve androgen deprivation therapy (ADT) clinical activity.</Para>
              <Para TextBreak="No">However, as we introduce biologic agents such as bevacizumab to earlier disease populations that have longer OSs, investigators need to ensure that these agents are not increasing other morbidities such as cardiovascular disease. Men with prostate cancer have a higher rate of non-cancer mortality than men in the general population with some of this excess mortality related to treatment. Keating and collogues, in an observational study of 73,196 patients with prostate cancer from the SEER database, showed that the use of GnRH agonists was associated with increased risk of incident of diabetes, coronary heart disease, myocardial infarction, and sudden cardiac arrest [<CitationRef CitationID="CR46_18">45</CitationRef>]. An increased risk of diabetes and coronary heart disease was evident even with 1–4 months of initiating GnRH analog therapy. Thus, the addition of any agent to ADT must consider the impact on non-cancer morbidity and mortality. Ultimately, to bring such a combination of bevacizumab plus ADT therapy forward into an asymptomatic population will require establishing the safety of this combination along with understanding the biological and clinical effects of these therapies combined in androgen-dependent patients. Several trials are currently ongoing to further explore the safety and clinical activity of anti-angiogenesis agents in combination with ADT.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec9">
            <Heading>Future Directions</Heading>
            <Para TextBreak="No">The search for better angiogenic inhibitors in terms of potency, tolerability, safety, and efficacy is a burgeoning field in all aspects of cancer research. It holds true promise with remarkable objective tumor response in synergism with conventional cytotoxic chemotherapy. Bevacizumab has a significant potential to augment the impact of other cytotoxic agents when given in combination. However, a significant limitation for bevacizumab as well as other agents working along related pathways is the concerns over debilitating toxicities in some patients. In this context, studies investigating the optimal dosing regimen and duration of treatment with bevacizumab combination therapies are needed to help circumvent a number of the toxicities. As in other malignancies, biomarkers and prognostic models that select patients for angiogenesis therapy are desperately needed. These data to date remain encouraging, and the ongoing trials will help determine the role of bevacizumab in patients with prostate cancer.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_18.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_18">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Ferrara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HP</Initials>
                  <FamilyName>Gerber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>LeCouter</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">The biology of VEGF and its receptors</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>669</FirstPage>
                <LastPage>76</LastPage>
                <Occurrence Type="PID">
                  <Handle>12778165</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nm0603-669</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXktFOnur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–76.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_18">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Winer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>362</VolumeID>
                <FirstPage>841</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>7683111</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/362841a0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXktVKju7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_18">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IJ</Initials>
                  <FamilyName>Fidler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Ellis</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">The implications of angiogenesis for the biology and therapy of cancer metastasis</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>79</VolumeID>
                <FirstPage>185</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>7525076</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0092-8674(94)90187-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXmslOltLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_18">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1971</Year>
                <ArticleTitle Language="En">Tumor angiogenesis: therapeutic implications</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>285</VolumeID>
                <FirstPage>1182</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>4938153</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM197108122850711</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE38%2FgvVCqsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_18">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1972</Year>
                <ArticleTitle Language="En">Anti-angiogenesis: new concept for therapy of solid tumors</ArticleTitle>
                <JournalTitle>Ann Surg</JournalTitle>
                <VolumeID>175</VolumeID>
                <FirstPage>409</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>5077799</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00000658-197203000-00014</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE3s%2FitV2gtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_18">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1975</Year>
                <ArticleTitle Language="En">Tumor angiogenesis: a possible control point in tumor growth</ArticleTitle>
                <JournalTitle>Ann Intern Med</JournalTitle>
                <VolumeID>82</VolumeID>
                <FirstPage>96</FirstPage>
                <LastPage>100</LastPage>
                <Occurrence Type="PID">
                  <Handle>799908</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.7326/0003-4819-82-1-96</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE2s7otVSlsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 1975;82:96–100.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_18">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Wray</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Rilo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Ahmad</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Colon cancer angiogenesis and antiangiogenic therapy</ArticleTitle>
                <JournalTitle>Expert Opin Investig Drugs</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>631</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>15174949</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1517/13543784.13.6.631</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXktlyqsLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wray CJ, Rilo HL, Ahmad SA. Colon cancer angiogenesis and antiangiogenic therapy. Expert Opin Investig Drugs 2004;13:631–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_18">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Jaeger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Weidner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Chew</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>154</VolumeID>
                <FirstPage>69</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>7539869</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(01)67230-6</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2M3psFWjsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995;154:69–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_18">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Macchiarini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Fontanini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Hardin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Squartini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Angeletti</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Relation of neovascularisation to metastasis of non-small-cell lung cancer</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>340</VolumeID>
                <FirstPage>145</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>1378165</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0140-6736(92)93217-B</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK38zis1CltA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992;340:145–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_18">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Weidner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Pozza</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>84</VolumeID>
                <FirstPage>1875</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>1281237</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/84.24.1875</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s%2FpsFWhtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_18">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Weidner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Semple</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Welch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>324</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>1701519</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM199101033240101</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3M%2FnsVWquw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma. N Engl J Med 1991;324:1–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_18">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Weidner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Carroll</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Flax</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>143</VolumeID>
                <FirstPage>401</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7688183</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3szktlWqtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_18">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Siegal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MK</Initials>
                  <FamilyName>Brawer</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Topography of neovascularity in human prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>75</VolumeID>
                <FirstPage>2545</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>7537624</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(19950515)75:10&lt;2545::AID-CNCR2820751022&gt;3.0.CO;2-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2M3lsVCntg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995;75:2545–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_18">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Browder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Palmblad</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Angiogenesis research: guidelines for translation to clinical application</ArticleTitle>
                <JournalTitle>Thromb Haemost</JournalTitle>
                <VolumeID>86</VolumeID>
                <FirstPage>23</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>11487011</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXlsVeks74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001;86:23–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_18">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Kerbel</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents</ArticleTitle>
                <JournalTitle>Bioessays</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>31</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>1722975</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/bies.950130106</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK387is1SitQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13:31–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_18">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HP</Initials>
                  <FamilyName>Gerber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Ferrara</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>671</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>15705858</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtVWnsb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_18">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Jain</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>307</VolumeID>
                <FirstPage>58</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>15637262</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.1104819</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXnvFar</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_18">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">VEGF signaling inhibitors: more pro-apoptotic than antiangiogenic</ArticleTitle>
                <JournalTitle>Cancer Metastasis Rev</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>443</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>17786538</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s10555-007-9071-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1yktLnJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than antiangiogenic. Cancer Metastasis Rev 2007;26:443–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_18">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Ferrara</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Role of vascular endothelial growth factor in regulation of angiogenesis</ArticleTitle>
                <JournalTitle>Kidney Int</JournalTitle>
                <VolumeID>56</VolumeID>
                <FirstPage>794</FirstPage>
                <LastPage>814</LastPage>
                <Occurrence Type="PID">
                  <Handle>10469350</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1523-1755.1999.00610.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXlvF2gt7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ferrara N. Role of vascular endothelial growth factor in regulation of angiogenesis. Kidney Int 1999;56:794–814.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_18">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Ferrara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Davis-Smyth</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">The biology of vascular endothelial growth factor</ArticleTitle>
                <JournalTitle>Endrocrinology</JournalTitle>
                <VolumeID>18</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>22</LastPage>
              </BibArticle>
              <BibUnstructured>Ferrara N and Davis-Smyth T. The biology of vascular endothelial growth factor. Endrocrinology 1997;18:1–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_18">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FA</Initials>
                  <FamilyName>Ferrer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Expression of vascular endothelial receptors inhuman prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>43</VolumeID>
                <FirstPage>567</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(99)00156-9</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ferrer FA, Miller LJ, et al. Expression of vascular endothelial receptors inhuman prostate cancer. Urology 1999;43:567–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_18">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FA</Initials>
                  <FamilyName>Ferrer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of FEGG by human prostate cancer cells</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>157</VolumeID>
                <FirstPage>2329</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>9146665</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(01)64775-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmsVehsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ferrer FA, Miller LJ, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of FEGG by human prostate cancer cells. J Urol 1997;157:2329–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_18">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Duque</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Loughlin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>45</VolumeID>
                <FirstPage>523</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(99)00167-3</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Duque J, Loughlin K, et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;45:523–27.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_18">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Duque</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KR</Initials>
                  <FamilyName>Loughlin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen</ArticleTitle>
                <JournalTitle>Clinics</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>401</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>17072437</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1590/S1807-59322006000500006</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Duque JL, Loughlin KR, et al. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics 2006;61(5):401–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_18">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bok</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">VEGF and bFGF urine levels as predictors of outcome in hormone refractory prostate cancer patients: a CALGB study</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <FirstPage>2533</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11289126</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXisVSksrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bok R, Halabi S, et al. VEGF and bFGF urine levels as predictors of outcome in hormone refractory prostate cancer patients: a CALGB study. Cancer Res 2001;61:2533–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_18">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>George</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Prognostic significance of plasma vascular endothelial growth factor (VEGF) levels in patients with hormone refractory prostate cancer: a CALGB study</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>1932</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11448906</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3MzpslegtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>George D, Halabi S, et al. Prognostic significance of plasma vascular endothelial growth factor (VEGF) levels in patients with hormone refractory prostate cancer: a CALGB study. Clin Cancer Res 2001;7:1932–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_18">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IBJK</Initials>
                  <FamilyName>Joseph</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Androgens regulate vascular endothelial growth factor content in normal and malignant prostate tissues</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>2507</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="PID">
                  <Handle>9815654</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXisFSjsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Joseph IBJK, Nelson JB, et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostate tissues. Clin Cancer Res 1997;3:2507–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_18">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Jain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Safabakhsh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>95</VolumeID>
                <FirstPage>10820</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>9724788</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.95.18.10820</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXlvFWnu78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jain A, Safabakhsh N, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1998;95:10820–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_18">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Kirschenbaum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Inhibition of vascular endothelial cell growth factor suppresses the in vitro growth of human prostate cancer tumors</ArticleTitle>
                <JournalTitle>Urol Oncol</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>3</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>21227046</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S1078-1439(97)00001-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXjslOqur0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kirschenbaum A, Wang J, et al. Inhibition of vascular endothelial cell growth factor suppresses the in vitro growth of human prostate cancer tumors. Urol Oncol 1997;3:3–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_18">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Borgstrom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Bourdon</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro-tumors in vivo</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>35</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>9537593</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0045(19980401)35:1&lt;1::AID-PROS1&gt;3.0.CO;2-O</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXisFCks74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Borgstrom P, Bourdon M, et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro-tumors in vivo. Prostate 1998;35:1–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_18">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Melynk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Simmerman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in pre-clinical model</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>161</VolumeID>
                <FirstPage>960</FirstPage>
                <LastPage>3</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(01)61829-9</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Melynk O, Simmerman M, et al. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in pre-clinical model. J Urol 1999;161:960–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_18">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Hammarsten</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>24</IssueID>
                <FirstPage>7431</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>17189416</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-06-1895</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtlCrtrzP</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hammarsten P, Halin S, et al. Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res 2006;12(24):7431–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_18">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Hurwitz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Fehrenbacher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Novotny</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Cartwright</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Hainsworth</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>350</VolumeID>
                <FirstPage>2335</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>15175435</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa032691</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXks1Gjt74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_18">
              <CitationNumber>34</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>BJ</Initials>
                  <FamilyName>Giantonio</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Catalano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Meropol</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>O’Dwyer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Mitchell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SR</Initials>
                  <FamilyName>Alberts</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Schwartz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AB</Initials>
                  <FamilyName>Benson</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <BookTitle>High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200</BookTitle>
              </BibBook>
              <BibUnstructured>Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. ASCO 2005 (abstract 2).</BibUnstructured>
            </Citation>
            <Citation ID="CR35_18">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sandler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Gray</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Perry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>355</VolumeID>
                <IssueID>24</IssueID>
                <FirstPage>2542</FirstPage>
                <LastPage>50</LastPage>
                <Occurrence Type="PID">
                  <Handle>17167137</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa061884</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtlWqsbzI</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542–50.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_18">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gralow</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100)</ArticleTitle>
                <JournalTitle>Breast Cancer Res Treat</JournalTitle>
                <VolumeID>94</VolumeID>
                <IssueID>suppl 1</IssueID>
                <FirstPage>S6</FirstPage>
                <BibComments>Abstract 3</BibComments>
              </BibArticle>
              <BibUnstructured>Miller K, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005;94(suppl 1):S6 (abstract 3).</BibUnstructured>
            </Citation>
            <Citation ID="CR37_18">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LG</Initials>
                  <FamilyName>Presta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>O’Connor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>4593</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>9377574</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmslKqtLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Presta LG, Chen H, O’Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–99.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_18">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Reese</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Fratesi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Corry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>65</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1525-1411.2001.32007.x</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Reese DM, Fratesi P, Corry M, et al. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate 2001;3:65–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_18">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Picus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Rini</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006</ArticleTitle>
                <JournalTitle>Proc Am Soc Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>1578</FirstPage>
              </BibArticle>
              <BibUnstructured>Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003;22:1578.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_18">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Savarese</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Hars</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>2509</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>11331330</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjvVelurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 2001;19(9):2509–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_18">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: cancer and Leukemia Group B 99813</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>98</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>2592</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>14669278</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.11829</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXit1yhtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: cancer and Leukemia Group B 99813. Cancer 2003;98(12):2592–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_18">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Lorenzo</FamilyName>
                  <Particle>Di</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Fossa</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>54</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1089</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>18276061</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eururo.2008.01.082</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008;54(5):1089–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_18">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>YM</Initials>
                  <FamilyName>Ning</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2010</Year>
                <ArticleTitle Language="En">A phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>28</VolumeID>
                <FirstPage>2070</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>20308663</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2009.25.4524</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BC3cXmtlSksrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ning YM, Gulley JL, Arlen PM, et al. A phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:2070–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_18">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2010</Year>
                <ArticleTitle Language="En">A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401</ArticleTitle>
                <JournalTitle>ASCO Annual Meeting Proceedings J Clin Oncol</JournalTitle>
                <VolumeID>28</VolumeID>
                <FirstPage>LBA4511</FirstPage>
              </BibArticle>
              <BibUnstructured>Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. ASCO Annual Meeting Proceedings J Clin Oncol 2010;28:LBA4511.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_18">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NL</Initials>
                  <FamilyName>Keating</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>O’Malley</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <IssueID>27</IssueID>
                <FirstPage>4448</FirstPage>
                <LastPage>56</LastPage>
                <Occurrence Type="PID">
                  <Handle>16983113</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.06.2497</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtVyisrrK</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Keating NL, O’Malley AJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448–56.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
